SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Prevnar

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed. Next-generation 25-valent pediatric vaccine is in Phase 3 (started May 2026); 35-valent adult candidate expected to enter clinical development by end of 2026, with potential approval likely several years away.
Why 4/10
Prevnar 20 is already FDA-approved and commercially marketed for both adults and pediatrics with no pending PDUFA or pivotal readout for the currently marketed product. The next catalysts are Phase 3 readouts for the 25-valent pediatric successor (25vPnC, started May 2026) and clinical entry of the 35-valent adult candidate, both >12 months from binary outcome. At ~10% of Pfizer's total revenue, Prevnar is a major product but not a single-asset binary for a $170B diversified pharma.
Actionable Insight NEUTRAL

Watch for Phase 3 data readouts from Pfizer's 25-valent pediatric pneumococcal vaccine (25vPnC) and the clinical development start of the 35-valent adult candidate, both expected within the next 12-18 months. Near-term, monitor quarterly Prevnar sales trends for market share shifts against Merck's Capvaxive and Vaxcyte's VAX-31, which posted positive Phase 3 results in October 2026.

Price Chart

Loading chart...

Executive Summary

Prevnar is Pfizer's blockbuster pneumococcal vaccine franchise, anchored by Prevnar 20 (PCV20), which is FDA-approved for both adults (2021) and children (2023). The franchise generated $6.49 billion in 2025, making it the world's top-selling vaccine portfolio, though Q3 2026 sales declined 10% year-over-year amid competition from Merck's Capvaxive (PCV21, approved 2024) and the threat of Vaxcyte's VAX-31, which posted positive Phase 3 results in October 2026. Pfizer is defending the franchise with a 25-valent pediatric vaccine now in Phase 3 and a 35-valent adult candidate expected to enter clinical development by end of 2026. As an already-approved, commercialized product at a diversified pharma giant, Prevnar has no near-term binary regulatory catalyst.

How It Works

Prevnar is a vaccine that trains the immune system to recognize and fight Streptococcus pneumoniae bacteria. It works by presenting pieces of the bacterial capsule (polysaccharides) linked to a carrier protein, which triggers the body to produce antibodies against up to 20 different strains (serotypes) of the bacteria. This prevents infections like pneumonia, meningitis, and bloodstream infections caused by these bacteria.

Trial Status

Prevnar 20 is FDA-approved and commercially marketed for adults (June 2021) and pediatrics (April 2023). Pfizer's next-gen 25-valent pediatric vaccine (25vPnC/PF-07872412) advanced to Phase 3 in May 2026 after strong Phase 2 data. A 35-valent adult candidate is planned for clinical entry by end of 2026.

The Two-Sided Case

▲ Bull Case6
Prevnar is the world's highest-revenue vaccine franchise, generating $6.49 billion in 2025, roughly 10% of Pfizer's total revenue (source: PharmaShots Top 20 Vaccines 2026).
Prevnar 20 is approved for both adults (June 2021) and pediatrics (April 2023), giving it the broadest approved age indication among pneumococcal conjugate vaccines.
Pfizer's next-gen 25-valent pediatric vaccine (25vPnC/PF-07872412) showed strong Phase 2 data at IDWeek 2026 with serotype 3 antibody levels ~15-fold higher than Prevnar 20, and has advanced to Phase 3.
Pfizer plans to bring a fifth-generation 35-valent adult vaccine candidate into clinical development by end of 2026, extending the franchise lifecycle.
The CDC expanded pneumococcal vaccine recommendations in October 2024 to all adults aged 50+ (down from 65), expanding the addressable market for Prevnar 20.
Pfizer raised full-year 2026 revenue guidance to $62-64B and EPS to $2.95-3.05 after a Q3 2026 beat, with non-COVID product revenue growing 7% operationally.
▼ Bear Case5
Prevnar family revenue declined 10% in Q3 2026 year-over-year, driven by lower vaccination rates and market share erosion (per Pfizer's Q3 2026 8-K earnings release).
Merck's Capvaxive (PCV21), approved June 2024, covers 21 serotypes and was designed specifically for adults, directly competing with Prevnar 20 in the adult market.
Vaxcyte's VAX-31 met all primary endpoints in its pivotal Phase 3 OPUS-1 trial (October 2026), showing non-inferiority to Prevnar 20 on all 20 shared serotypes, threatening Pfizer's long-term franchise.
Pfizer's analyst consensus is mixed: 13 Buy/Strong Buy vs 20 Hold/Sell/Sell ratings, with a mean price target of $29.26, below the current ~$30 stock price (implying -2.5% downside).
Several large institutional holders trimmed or exited PFE in Q2 2026, including Wellington Management (-44%), Marshall Wace (-95%), and Point72 (full exit).

Upcoming Catalysts

  • Phase 3 data readouts for 25-valent pediatric pneumococcal vaccine (25vPnC, PF-07872412)
  • Clinical development start for 35-valent adult pneumococcal vaccine candidate (expected by end of 2026)
  • Quarterly Prevnar family sales trends and market share vs Merck's Capvaxive and Vaxcyte's VAX-31

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 9

Hover a chip for the title
1 fda.gov2 pfizer.com3 pharmashots.com4 pfizer.com5 businesswire.com6 investors.vaxcyte.com7 sec.gov8 cdc.gov9 pharmaphorum.com